Device Trial Radar · NCT06271590
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,605
Planned (sponsor's estimate)
Start
May 20, 2025
Primary completion
Nov 2028
Study completion Nov 2031
Sponsor
- Lead sponsor
- Concept Medical Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Cardiovascular Research Foundation, New York
- First posted
- Feb 22, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm). A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of \~50% of enrollees.
Conditions
- Coronary Artery Disease
- Native Coronary Artery Stenosis
- Cardiovascular Diseases
Interventions
Sirolimus Drug Coated BalloonDevice
Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
Drug eluting stents (DES)Device
For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target lesion failure (TLF)Time frame: within 12 months
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Dignity Health - Mercy Gilbert Medical Center
Gilbert, Arizona · Not yet recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Not yet recruiting
Clearwater Cardiovascular and Interventional Consultants
Clearwater, Florida · Recruiting
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.